SCHEMBL6793273

SCHEMBL6793273

O=C(O)c1[nH]nc2c1Cc1ccc(O)cc1-2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALPL P05186 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MEN1 O00255 1/20 0.47
CLK1 P49759 1/20 0.47
KMT2A Q03164 1/20 0.47
CHEK1 O14757 14/20 0.46
GSR P00390 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2C8 P10632 1/20 0.40
CYP2C9 P11712 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793178 0.91 KDM4E (0.53) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6792881 0.87 MEN1 (0.58) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6787018 0.84 CHEK1 (0.46) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6791583 0.81 MEN1 (0.68) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6795109 0.79 MEN1 (0.69) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6787223 0.76 MEN1 (0.80) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6799356 0.76 CHEK1 (0.48) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6795304 0.75 CCNA2 (0.54) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6794407 0.72 MEN1 (0.61) KDM4EALPLHSD17B10MEN1CLK1
SCHEMBL6792195 0.72 MEN1 (0.46) KDM4EALPLHSD17B10MEN1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 KDM4E 2167/4885ALPL 3297/4885HSD17B10 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.